255 related articles for article (PubMed ID: 15816536)
21. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
24. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm.
Mase T; Funahashi H; Koshikawa T; Imai T; Nara Y; Tanaka Y; Nakao A
Endocr J; 2003 Apr; 50(2):173-7. PubMed ID: 12803237
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
27. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
28. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
29. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Arch Surg; 2004 Jan; 139(1):83-8. PubMed ID: 14718282
[TBL] [Abstract][Full Text] [Related]
31. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):133-41. PubMed ID: 15757200
[TBL] [Abstract][Full Text] [Related]
32. [Fine-needle aspiration biopsy of the thyroid nodule: uses and limitations].
Hayashi N; Kitaoka M
Nihon Rinsho; 2007 Nov; 65(11):2003-7. PubMed ID: 18018562
[TBL] [Abstract][Full Text] [Related]
33. Delta Np73 expression in thyroid neoplasms originating from follicular cells.
Ito Y; Uramoto H; Funa K; Yoshida H; Jikuzono T; Asahi S; Higashiyama T; Tomoda C; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Miyauchi A
Pathology; 2006 Jun; 38(3):205-9. PubMed ID: 16753740
[TBL] [Abstract][Full Text] [Related]
34. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
35. Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Satacińska-Los E; Kulig A; Włoch J
Pol J Pathol; 2005; 56(1):27-35. PubMed ID: 15921011
[TBL] [Abstract][Full Text] [Related]
36. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
37. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
38. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of p107 is correlated with anaplastic transformation in papillary carcinoma of the thyroid.
Ito Y; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Miyauchi A
Anticancer Res; 2003; 23(5A):3819-24. PubMed ID: 14666683
[TBL] [Abstract][Full Text] [Related]
40. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
